Novo Nordisk A/S (NVO) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - General industria. La empresa tiene su sede en Bagsvaerd, Denmark. El CEO actual es Maziar Mike Doustdar.
NVO tiene fecha de IPO 1981-04-30, 77,406 empleados a tiempo completo, cotiza en el New York Stock Exchange, una capitalización de mercado de $174.74B.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 that researches, develops, manufactures, and distributes medications globally across Europe, the Middle East, Africa, China, and North America. The company operates through two primary segments: Diabetes and Obesity Care, which offers treatments for diabetes, obesity, and cardiovascular conditions, and Rare Disease, which focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Beyond pharmaceutical products, Novo Nordisk provides delivery devices such as insulin pens and growth hormone pens, as well as digital health solutions including smart insulin pens and dose guidance applications. The company has established strategic collaborations with UNICEF on childhood obesity initiatives and with Valo Health to develop cardiometabolic therapies.
